(1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one

Product Name‌: (1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one (Edoxaban Impurity 80)
‌CAS No.‌: 139893-81-5

🔬 ‌Product Overview‌
A critical pharmaceutical intermediate used in synthesizing ‌Edoxaban‌ (CAS 480449-70-5), a direct oral anticoagulant (DOAC) for preventing stroke and systemic embolism in atrial fibrillation patients. With a purity of ‌≥97%‌ (HPLC-certified), it ensures precise quality control in API manufacturing and R&D for next-generation anticoagulants. Available in bulk quantities (1kg–25kg) with industrial-grade packaging options.

📊 ‌Key Advantages‌
✅ ‌High Purity‌: ≥97% (HPLC/GC-certified), minimizing batch variability in API production.
📦 ‌Custom Packaging‌: Flexible formats (1kg, 5kg, 25kg) for lab and industrial-scale needs.
💊 ‌Strategic Relevance‌: Core intermediate for Edoxaban, a $1.2B+ market drug with expanding cardiovascular applications.

💊 ‌Applications‌

1. ‌Anticoagulant Production‌: Essential for Edoxaban API synthesis.

2. ‌Pharmaceutical R&D‌: Supports development of novel thrombin inhibitors.

3. ‌Global Supply‌: Exported for chemical reagents and generic drug manufacturing.

📜 ‌Quality Certification‌

• ‌Testing Standards‌: HPLC, GC, NMR, and mass spectrometry.

• ‌Compliance‌: Meets ISO 9001 and ICH guidelines for intermediates.

🌍 ‌Market Trends‌
Demand for Edoxaban intermediates is surging due to ‌patent expirations‌ (2024–2026) and rising global prevalence of cardiovascular diseases. The DOAC market is projected to grow at ‌8.4% CAGR‌ (2025–2030), with Asia-Pacific dominating generic API production. Suppliers offering ‌GMP-compliant batches‌ are prioritized by manufacturers targeting cost-effective anticoagulant solutions.